within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD01_Carmustine;

model Carmustine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.333333333333333e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.03,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.02,
    k12 = 2.0833333333333334e-06,
    k21 = 2.0833333333333334e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Carmustine</td></tr><tr><td>ATC code:</td><td>L01AD01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>30</td><td>L</td></tr>
    <tr><td>clearance:</td><td>200</td><td>ml/min/m^2</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Carmustine (BCNU) is a nitrosourea alkylating agent used as an antineoplastic (anticancer) drug, mainly for the treatment of brain tumors, multiple myeloma, and lymphomas. It is cytotoxic and works by cross-linking DNA and RNA, thereby inhibiting DNA replication and transcription. Carmustine is approved and still used clinically, particularly for brain tumors due to its ability to cross the blood-brain barrier.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients, typical dosing regimen; parameters for intravenous administration.</p><h4>References</h4><ol><li><p>Tran, L, et al., &amp; Huitema, AD (2010). Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. <i>Human antibodies</i> 19(1) 7–13. DOI:<a href=\"https://doi.org/10.3233/HAB-2010-0215\">10.3233/HAB-2010-0215</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20555126/\">https://pubmed.ncbi.nlm.nih.gov/20555126</a></p></li><li><p>Jackson, NC, et al., &amp; Sharma, HL (1992). Cell-targeted 114Inm and drug (BCNU) combination therapy in a rat acute lymphoblastic leukaemia. <i>Nuclear medicine communications</i> 13(8) 614–619. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1513524/\">https://pubmed.ncbi.nlm.nih.gov/1513524</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01AD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Carmustine;
